Date of Report (Date of earliest event reported): November 20, 2003
BioMarin Pharmaceutical Inc.
(Exact name of registrant as specified in its charter)
| Delaware (State or other jurisdiction of incorporation or organization) |
000-26727 (Commission File Number) |
68-0397820 (IRS Employer Identification No.) |
| 371
Bel Marin Keys Boulevard, Suite 210, Novato, California (Address of principal executive offices) |
94949 (Zip Code) |
| Registrant's telephone number, including area code: | (415) 884-6700 |
Not Applicable
(Former name or former address, if changed since last report)
On November 20, 2003, BioMarin Pharmaceutical Inc. (the “Registrant”), issued a press release regarding the Registrant’s plans to begin clinical trials with Phenoptin for the treatment of PKU and the Registrant’s co-development agreement with Merck Eprova AG, for the manufacturing and supply of Phenoptin. The Registrant’s press release issued on November 20, 2003 is attached hereto as Exhibit 99.1.
(a) Financial Statements of Business Acquired.
Not Applicable.
(b) Pro Forma Financial Information.
Not Applicable.
(c) Exhibits.
Exhibit 99.1 Press Release of the Registrant dated November 20, 2003.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| BioMarin Pharmaceutical Inc., a Delaware corporation |
| Date: November 20, 2003 | By: /s/ Louis Drapeau Louis Drapeau Chief Financial Officer |
Exhibit No. Description
Exhibit 99.1 Press Release of the Registrant dated November 20, 2003.